|
Re: patients in clinical trial overwhelmingly prefer subcutaneous herceptin administr
I appreciate those who are taking a cautious approach in our behalf.
However, I also believe there are those whose life situations make it next to impossible for them to take on the difficulties involved with IV treatments (and risks involved with IV treaments); risks due to aging and/or other concomitant health conditions that would not be significant risks if administration was by sub-Q injection; and the major time commitment away from work and family obligations some people have in order to just survive.
How can these be "counted", to measure in balance with being cautious in our behalf while watching Europe come up with better answers for us? And why don't we have an equivalent trial investigation to look to for results "in our behalf", or is there one even allowed to happen?
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|
Hybrid Mode
